
Edwards Lifesciences (EW) Stock Forecast & Price Target
Edwards Lifesciences (EW) Analyst Ratings
Bulls say
Edwards Lifesciences is well-positioned in the structural heart disease market with a diverse portfolio of products, a strong global presence, and a solid track record of growth. The company's financial performance and latest guidance, including expectations for increased revenue and EPS, reflect its continued strength in the market. With multiple catalysts on the horizon, including potential expansions into new indications and product launches, Edwards Lifesciences has potential for further growth and market leadership.
Bears say
Edwards Lifesciences is a global leader in the rapidly growing TAVR market, with a significant share in both the U.S. and global markets. However, the company's recent proposal to remove the CMS Coverage with Evidence Development (CED) requirement for TAVR procedures may not have as significant of an impact on procedure volume as initially anticipated. Moreover, while EW's innovative TAVR device, SAPIEN X4, is highly anticipated, there is potential for increased competition from new entrants or newer innovations from existing competitors. Additionally, the company's lack of diversification in its product portfolio, with a heavy reliance on TAVR for revenue, could pose a risk in the future.
This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.
Edwards Lifesciences (EW) Analyst Forecast & Price Prediction
Start investing in Edwards Lifesciences (EW)
Order type
Buy in
Order amount
Est. shares
0 shares